![Christopher Gerry](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Gerry
General Counsel at
FAETH THERAPEUTICS, INC.
Net worth: 23 825 $ as of 2026-06-29
Profile
Christopher W.
Gerry is currently Secretary & General Counsel at Faeth Therapeutics, Inc., a position starting in 2026.
Formerly, Mr. Gerry was Vice President & Deputy General Counsel at AVROBIO, Inc. from 2021 to 2022 and an Associate at Cooley LLP from 2013 to 2019.
Education includes undergraduate studies at Dickinson College and graduate studies at Boston University School of Law.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-09 | 953 ( 0% ) | 23 825 $ | 2026-06-29 |
Christopher Gerry active positions
| Companies | Position | Start |
|---|---|---|
| FAETH THERAPEUTICS, INC. | General Counsel | 2022-06-30 |
Former positions of Christopher Gerry
| Companies | Position | End |
|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Corporate Officer/Principal | 2022-06-30 |
Cooley LLP
 Cooley LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 2019-09-30 |
Training of Christopher Gerry
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
10
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Dickinson College
 Dickinson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Boston University School of Law
 Boston University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVROBIO, Inc.
 AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose | Health Technology |
Sensei Biotherapeutics, Inc.
 Sensei Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops immunotherapies for cancers and infectious disease | Health Technology |
- Stock Market
- Insiders
- Christopher Gerry
